Search Results - "Kim, Edward S."

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases by Yang, James Chih-Hsin, Schuler, Martin, Popat, Sanjay, Miura, Satoru, Heeke, Simon, Park, Keunchil, Märten, Angela, Kim, Edward S

“…Limited clinical data are available regarding the efficacy of EGFR tyrosine kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR…”
Get more information

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement by Kim, Edward S, Bruinooge, Suanna S, Roberts, Samantha, Ison, Gwynn, Lin, Nancy U, Gore, Lia, Uldrick, Thomas S, Lichtman, Stuart M, Roach, Nancy, Beaver, Julia A, Sridhara, Rajeshwari, Hesketh, Paul J, Denicoff, Andrea M, Garrett-Mayer, Elizabeth, Rubin, Eric, Multani, Pratik, Prowell, Tatiana M, Schenkel, Caroline, Kozak, Marina, Allen, Jeff, Sigal, Ellen, Schilsky, Richard L

“…Purpose The primary purposes of eligibility criteria are to protect the safety of trial participants and define the trial population. Excessive or overly…”
Get full text

Relationship between MLH1, PMS2, MSH2 and MSH6 gene‐specific alterations and tumor mutational burden in 1057 microsatellite instability‐high solid tumors by Salem, Mohamed E., Bodor, J. Nicholas, Puccini, Alberto, Xiu, Joanne, Goldberg, Richard M., Grothey, Axel, Korn, W. Michael, Shields, Anthony F., Worrilow, William M, Kim, Edward S., Lenz, Heinz‐Josef, Marshall, John L., Hall, Michael J.

“…Microsatellite instability‐high (MSI‐H) and tumor mutational burden (TMB) are predictive biomarkers for immune‐checkpoint inhibitors (ICIs). Still, the…”
Get full text

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group by Lin, Nancy U, Prowell, Tatiana, Tan, Antoinette R, Kozak, Marina, Rosen, Oliver, Amiri-Kordestani, Laleh, White, Julia, Sul, Joohee, Perkins, Louise, Beal, Katherine, Gaynor, Richard, Kim, Edward S

“…Purpose Broadening trial eligibility to improve accrual and access and to better reflect intended-to-treat populations has been recognized as a priority…”
Get full text

Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer by Judd, Julia, Abdel Karim, Nagla, Khan, Hina, Naqash, Abdul Rafeh, Baca, Yasmine, Xiu, Joanne, VanderWalde, Ari M, Mamdani, Hirva, Raez, Luis E, Nagasaka, Misako, Pai, Sachin Gopalkrishna, Socinski, Mark A, Nieva, Jorge J, Kim, Chul, Wozniak, Antoinette J, Ikpeazu, Chukwuemeka, de Lima Lopes, Jr, Gilberto, Spira, Alexander I, Korn, W Michael, Kim, Edward S, Liu, Stephen V, Borghaei, Hossein

“…is the most commonly mutated oncogene in NSCLC and development of direct KRAS inhibitors has renewed interest in this molecular variant. Different mutations…”
Get full text

The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer by Smeltzer, Matthew P, Wynes, Murry W, Lantuejoul, Sylvie, Soo, Ross, Ramalingam, Suresh S, Varella-Garcia, Marileila, Meadows Taylor, Meghan, Richeimer, Kristin, Wood, Kelsey, Howell, Kristen E, Dalurzo, Mercedes Lilana, Felip, Enriqueta, Hollenbeck, Gina, Kerr, Keith, Kim, Edward S, Mathias, Clarissa, Pacheco, Jose, Postmus, Pieter, Powell, Charles, Tsuboi, Masahiro, Wistuba, Ignacio I, Wakelee, Heather A, Belani, Chandra P, Scagliotti, Giorgio V, Hirsch, Fred R

“…Access to targeted therapies for lung cancer depends on the accurate identification of patients' biomarkers through molecular testing. The International…”
Get more information

An Epithelial―Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance by AVERETT BYERS, Lauren, LIXIA DIAO, NILSSON, Monique B, GUDIKOTE, Jayanthi, TRAN, Hai, CARDNELL, Robert J. G, BEARSS, David J, WARNER, Steven L, FOULKS, Jason M, KANNER, Steven B, GANDHI, Varsha, KRETT, Nancy, JING WANG, ROSEN, Steven T, KIM, Edward S, HERBST, RoyS, BLUMENSCHEIN, George R, LEE, J. Jack, LIPPMAN, Scott M, KIAN ANG, K, MILLS, Gordon B, HONG, Waun K, WEINSTEIN, John N, SAINTIGNY, Pierre, WISTUBA, Ignacio I, COOMBES, Kevin R, MINNA, John D, HEYMACH, John V, GIRARD, Luc, PEYTON, Michael, LI SHEN, YOUHONG FAN, GIRI, Uma, TUMULA, Praveen K

“…Epithelial-mesenchymal transition (EMT) has been associated with metastatic spread and EGF receptor (EGFR) inhibitor resistance. We developed and validated a…”
Get full text

Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer by WELSH, James W, KOMAKI, Ritsuko, CHEN, Su S, HOLT, Jamie, ZHONGXING LIAO, BROWN, Paul, SULMAN, Erik, HEYMACH, John V, KIM, Edward S, STEA, Baldassarre, AMINI, Arya, MUNSELL, Mark F, UNGER, Wyatt, ALLEN, Pamela K, CHANG, Joe Y, WEFEL, Jeffrey S, MCGOVERN, Susan L, GARLAND, Linda L

“…Brain metastasis (BM) is a leading cause of death from non-small-cell lung cancer (NSCLC). Reasoning that activation of the epidermal growth factor receptor…”
Get full text

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial by Huber, Rudolf M, Hansen, Karin H, Paz-Ares Rodríguez, Luis, West, Howard L, Reckamp, Karen L, Leighl, Natasha B, Tiseo, Marcello, Smit, Egbert F, Kim, Dong-Wan, Gettinger, Scott N, Hochmair, Maximilian J, Kim, Sang-We, Langer, Corey J, Ahn, Myung-Ju, Kim, Edward S, Kerstein, David, Groen, Harry J M, Camidge, D Ross

“…We report updated data from a phase 2 randomized study evaluating brigatinib in crizotinib-refractory anaplastic lymphoma kinase-positive NSCLC. Patients were…”
Get more information

Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry by Zhang, Jianjun, Gold, Kathryn A, Lin, Heather Y, Swisher, Stephen G, Xing, Yan, Lee, J Jack, Kim, Edward S, William, Jr, William N

“…Tumor size is a known prognostic factor for early stage non-small-cell lung cancer (NSCLC), but its significance in node-positive and locally invasive NSCLC…”
Get more information

Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey by Waterhouse, David M, Harvey, R Donald, Hurley, Patricia, Levit, Laura A, Kim, Edward S, Klepin, Heidi D, Mileham, Kathryn Finch, Nowakowski, Grzegorz, Schenkel, Caroline, Davis, Courtney, Bruinooge, Suanna S, Schilsky, Richard L

“…The coronavirus disease 2019 (COVID-19) pandemic has disrupted all aspects of clinical care, including cancer clinical trials. In March 2020, ASCO launched a…”
Get more information

Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial by DOUILLARD, Jean-Yves, SHEPHERD, Frances A, WATKINS, Claire L, SPEAKE, Georgina, ARMOUR, Alison A, KIM, Edward S, HIRSH, Vera, MOK, Tony, SOCINSKI, Mark A, GERVAIS, Radj, LIAO, Mei-Lin, BISCHOFF, Helge, RECK, Martin, SELLERS, Mark V

“…PURPOSE In the phase III INTEREST trial, 1,466 pretreated patients with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive gefitinib…”
Get full text

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial by Kim, Edward S, MD, Hirsh, Vera, MD, Mok, Tony, Prof, Socinski, Mark A, Prof, Gervais, Radj, MD, Wu, Yi-Long, Prof, Li, Long-Yun, Prof, Watkins, Claire L, MSc, Sellers, Mark V, MSc, Lowe, Elizabeth S, MD, Sun, Yan, MD, Liao, Mei-Lin, Prof, Østerlind, Kell, MD, Reck, Martin, MD, Armour, Alison A, FRCR, Shepherd, Frances A, Prof, Lippman, Scott M, Prof, Douillard, Jean-Yves, Prof

“…Summary Background Two phase II trials in patients with previously-treated advanced non-small-cell lung cancer suggested that gefitinib was efficacious and…”
Get full text

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome by Ihle, Nathan T., Byers, Lauren A., Kim, Edward S., Saintigny, Pierre, Lee, J. Jack, Blumenschein, George R., Tsao, Anne, Liu, Suyu, Larsen, Jill E., Wang, Jing, Diao, Lixia, Coombes, Kevin R., Chen, Lu, Zhang, Shuxing, Abdelmelek, Mena F., Tang, Ximing, Papadimitrakopoulou, Vassiliki, Minna, John D., Lippman, Scott M., Hong, Waun K., Herbst, Roy S., Wistuba, Ignacio I., Heymach, John V., Powis, Garth

“…Background Mutations in the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) play a critical role in cancer cell growth and resistance to therapy…”
Get full text

The BATTLE trial: personalizing therapy for lung cancer by Kim, Edward S, Herbst, Roy S, Wistuba, Ignacio I, Lee, J Jack, Blumenschein, Jr, George R, Tsao, Anne, Stewart, David J, Hicks, Marshall E, Erasmus, Jr, Jeremy, Gupta, Sanjay, Alden, Christine M, Liu, Suyu, Tang, Ximing, Khuri, Fadlo R, Tran, Hai T, Johnson, Bruce E, Heymach, John V, Mao, Li, Fossella, Frank, Kies, Merrill S, Papadimitrakopoulou, Vassiliki, Davis, Suzanne E, Lippman, Scott M, Hong, Waun K

“…The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial represents the first completed prospective, biopsy-mandated,…”
Get more information

Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib by MORGILLO, Floriana, JONG KYU WOO, KIM, Edward S, WAUN KI HONG, LEE, Ho-Young

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been used to treat non-small cell lung cancer (NSCLC). However, the overall…”
Get full text

Clinicopathologic Features of Advanced Squamous NSCLC by Socinski, Mark A, Obasaju, Coleman, Gandara, David, Hirsch, Fred R, Bonomi, Philip, Bunn, Paul, Kim, Edward S, Langer, Corey J, Natale, Ronald B, Novello, Silvia, Paz-Ares, Luis, Pérol, Maurice, Reck, Martin, Ramalingam, Suresh S, Reynolds, Craig H, Spigel, David R, Stinchcombe, Thomas E, Wakelee, Heather, Mayo, Carlos, Thatcher, Nick

“…Lung cancer remains the leading cause of cancer-related death worldwide. NSCLC accounts for more than 85% of all lung cancers, and the prognosis for…”
Get more information

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report by Yang, James Chih-Hsin, Schuler, Martin, Popat, Sanjay, Miura, Satoru, Park, Keunchil, Passaro, Antonio, De Marinis, Filippo, Solca, Flavio, Märten, Angela, Kim, Edward S

“…Previously, we developed a database of 693 patients with NSCLC and uncommon mutations treated with afatinib. Here, we provide an update of >1000 patients, with…”
Get full text

Influence of Technologic Advances on Outcomes in Patients With Unresectable, Locally Advanced Non–Small-Cell Lung Cancer Receiving Concomitant Chemoradiotherapy by Liao, Zhongxing X., M.D, Komaki, Ritsuko R., M.D, Thames, Howard D., Ph.D, Liu, Helen H., Ph.D, Tucker, Susan L., Ph.D, Mohan, Radhe, Ph.D, Martel, Mary K., Ph.D, Wei, Xiong, M.D, Yang, Kunyu, M.D, Kim, Edward S., M.D, Blumenschein, George, M.D, Hong, Waun Ki, M.D, Cox, James D., M.D

“…Purpose In 2004, our institution began using four-dimensional computed tomography (4DCT) simulation and then intensity-modulated radiotherapy (IMRT)…”
Get full text

Modernizing Eligibility Criteria for Molecularly Driven Trials by Kim, Edward S, Bernstein, David, Hilsenbeck, Susan G, Chung, Christine H, Dicker, Adam P, Ersek, Jennifer L, Stein, Steven, Khuri, Fadlo R, Burgess, Earle, Hunt, Kelly, Ivy, Percy, Bruinooge, Suanna S, Meropol, Neal, Schilsky, Richard L

“…As more clinical trials of molecularly targeted agents evolve, the number of eligibility criteria seems to be increasing. The importance and utility of…”
Get full text